During a recent visit to Australia, Sheba’s Director General, Prof. Yitshak Kreiss, signed a letter of intent that would see Sheba partner with Peter Mac for the new POPSTAR II trial.
The POPSTAR II clinical trial, scheduled to begin in early 2023 at multiple sites, will compare two cutting-edge treatments for men with advanced prostate cancer – lutetium PSMA (LuPSMA) therapy and stereotactic ablative radiotherapy (SABR).
According to Peter Mac Chief Executive, Prof. Shelley Dolan, who visited Israel in early November, this latest collaboration is just another example of a growing international relationship between two leading medical centers.
“The international expansion of this clinical trial will boost access for men to innovative prostate cancer treatments,” Prof. Dolan explained. “Following the signing of an MOU between Peter Mac and Sheba Medical Center, it is fantastic to see it implemented for the benefit of people with cancer internationally.”
The aforementioned MOU was signed in May, promising to help both organizations collectively advance innovation and commercialization opportunities, research and scientific collaborations, opportunities for bilateral education and training, fellowship programs, staff exchange, and more.
Referring to the new agreement, Prof. Kreiss added: “We see our collaboration with Peter Mac as an important step toward strengthening our relationship with the Victorian Government in relation to innovation and clinical research. Peter Mac is an elite institution that is a leader in research and the development of novel treatments. It endeavors to change the future of medicine, mirroring Sheba’s vision via our ARC innovation center.”
As a global leader in oncologic treatment and research, Sheba is pleased to join forces with other leading health organizations to advance care for the benefit of patients worldwide.